Sign Up

Scynexis announces FDA approval of Brexafemme as the first and only oral non-azole treatment for vaginal yeast infections

Written by | 6 Jun 2021 | Infectious Diseases

Scynexis Inc.,. announced that the FDA has approved Brexafemme(ibrexafungerp tablets), for oral use in patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. Brexafemme which represents the first approved drug in a novel antifungal class in more than 20 years, was approved based on positive results from two Phase III studies in which oral ibrexafungerp demonstrated efficacy and a favorable tolerability profile in women with VVC.

Scynexis has partnered with Amplity Health, a leading global contract commercialization organization, to support U.S. commercialization of Brexafemme with commercial launch scheduled in the second half of this year.

Newsletter Icon

Register for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.